Serum cystatin-C and all-cause mortality in patients with hypertrophic cardiomyopathy: a retrospective cohort study
PeerJ · 2025
DOI: 10.7717/peerj.19631 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PeerJ, 2025. Verfasst von Lu Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Cystatin C, Cardiomyopathy, Hypertrophic. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan Science and Technology Program, China, National Natural Science Foundation of China, Sichuan Science and Technology Program.
Abstract (Originalsprache)
Background
Numerous studies across various populations have revealed that elevated cystatin-C levels are associated with an excessive risk of mortality. However, the prognostic value of cystatin-C remains unidentified in hypertrophic cardiomyopathy (HCM) patients. The objective of this study was to investigate whether serum cystatin-C could predict all-cause mortality independently in HCM patients.
Methods
Data from 456 HCM patients treated at West China Hospital were collected and stratified into two groups based on the median baseline serum cystatin-C level. All-cause mortality was the primary outcome. Cox regression models were used to analyze the association between cystatin-C levels and mortality risk.
Results
A total of 90 deaths were recorded over a median follow-up period of 4.67 years. Patients with higher cystatin-C levels had an increased risk of all-cause mortality (adjusted hazard ratio (HR): 2.11, 95% CI [1.30–3.42], p = 0.003) compared to those with lower levels. Time-dependent area under the curves (AUC) of cystatin-C in different time points, ranging from initial measurement to follow-up, showed a relatively stable fluctuation between 0.70 and 0.80. In comparison, the commonly used renal function markers, estimated glomerular filtration rate (eGFR) and serum creatinine, yielded lower AUC values. Restricted cubic spline curves showed that with median value of cystatin-C (1.01 mg/L) as reference, there was a gradual rise in risk of all-cause mortality with cystatin-C increasing. Subgroup analyses in female, in the patients ≥ 58 years old, and in the patients with eGFR ≥ 60 mL/min/1.73 m 2 consistently confirmed robustness of the main findings.
Conclusion
Elevated serum cystatin-C levels are associated with a higher risk of all-cause mortality in HCM patients, providing valuable prognostic information beyond traditional renal function markers such as eGFR and serum creatinine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
- Department of Cardiology, Hospital of Traditional Chinese Medicine, Shuangliu District, Chengdu, Sichuan, China.
- Karamay Hospital of Integrated Chinese and Western Medicine, Karamay, Xinjiang Uygur Autonomous Region, China.
Förderung
- Sichuan Science and Technology Program, China
- National Natural Science Foundation of China
- Sichuan Science and Technology Program
- the National Natural Science Foundation of China
- The Sichuan Science and Technology Program
Zitieren
APA
Liu, L., Zheng, Y., Ruan, H., Wang, Z., Chen, X., & He, S. (2025). Serum cystatin-C and all-cause mortality in patients with hypertrophic cardiomyopathy: a retrospective cohort study. PeerJ. https://doi.org/10.7717/peerj.19631
Vancouver
Liu L, Zheng Y, Ruan H, Wang Z, Chen X, He S. Serum cystatin-C and all-cause mortality in patients with hypertrophic cardiomyopathy: a retrospective cohort study. PeerJ. 2025. doi:10.7717/peerj.19631
BibTeX
@article{Liu2025,
author = {Liu, Lu and Zheng, Yi and Ruan, Haiyan and Wang, Ziqiong and Chen, Xiaoping and He, Sen},
title = {Serum cystatin-C and all-cause mortality in patients with hypertrophic cardiomyopathy: a retrospective cohort study},
journal = {PeerJ},
year = {2025},
doi = {10.7717/peerj.19631}
}
EUVIMED